Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Dec 8;12(12):3676.
doi: 10.3390/cancers12123676.

Translational Research in Ovarian Cancer

Maria Flavia Di Renzo  1   2 , Giorgio Valabrega  1   2
Affiliations
Editorial

Translational Research in Ovarian Cancer

Maria Flavia Di Renzo et al. Cancers (Basel). .

Abstract

Ovarian cancer is still the most lethal gynecologic malignancy with a median five-year survival of 48%, including the less malignant and early diagnosed cases [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Cancer Stat Facts: Ovarian Cancer. [(accessed on 3 December 2020)]; Available online: https://seer.cancer.gov/statfacts/html/ovary.html.
    1. McGee J., Bookman M., Harter P., Marth C., McNeish I., Moore K.N., Poveda A., Hilpert F., Hasegawa K., Bacon M., et al. Fifth Ovarian Cancer Consensus Conference: Individualized therapy and patient factors. Ann. Oncol. 2017;28:702–710. doi: 10.1093/annonc/mdx010. - DOI - PubMed
    1. McPherson A., Roth A., Laks E., Masud T., Bashashati A., Zhang A.W., Ha G., Biele J., Yap D., Wan A., et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat. Genet. 2016;48:758–767. doi: 10.1038/ng.3573. - DOI - PubMed
    1. Mirza M.R., Coleman R.L., González-Martín A., Moore K.N., Colombo N., Ray-Coquard I., Pignata S. The forefront of ovarian cancer therapy: Update on PARP inhibitors. Ann. Oncol. 2020;31:1148–1159. doi: 10.1016/j.annonc.2020.06.004. - DOI - PubMed
    1. Tew W.P., Lacchetti C., Ellis A., Maxian K., Banerjee S., Bookman M., Jones M.B., Lee J.M., Lheureux S., Liu J.F., et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J. Clin. Oncol. 2020;38:3468–3493. doi: 10.1200/JCO.20.01924. - DOI - PMC - PubMed

Publication types